Madrigal Pharmaceuticals, Inc. $MDGL Shares Sold by Segall Bryant & Hamill LLC

Segall Bryant & Hamill LLC cut its holdings in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) by 4.9% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 31,870 shares of the biopharmaceutical company’s stock after selling 1,650 shares during the period. Segall Bryant & Hamill LLC owned about 0.14% of Madrigal Pharmaceuticals worth $16,683,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in MDGL. Centaurus Financial Inc. raised its stake in shares of Madrigal Pharmaceuticals by 5.0% in the third quarter. Centaurus Financial Inc. now owns 709 shares of the biopharmaceutical company’s stock valued at $325,000 after acquiring an additional 34 shares in the last quarter. Farther Finance Advisors LLC grew its stake in Madrigal Pharmaceuticals by 34.6% during the 4th quarter. Farther Finance Advisors LLC now owns 140 shares of the biopharmaceutical company’s stock worth $82,000 after purchasing an additional 36 shares in the last quarter. Accent Capital Management LLC increased its holdings in Madrigal Pharmaceuticals by 64.9% during the 4th quarter. Accent Capital Management LLC now owns 94 shares of the biopharmaceutical company’s stock worth $55,000 after purchasing an additional 37 shares during the period. Swiss Life Asset Management Ltd increased its holdings in Madrigal Pharmaceuticals by 6.8% during the 4th quarter. Swiss Life Asset Management Ltd now owns 690 shares of the biopharmaceutical company’s stock worth $402,000 after purchasing an additional 44 shares during the period. Finally, HighTower Advisors LLC raised its position in Madrigal Pharmaceuticals by 4.1% in the 4th quarter. HighTower Advisors LLC now owns 1,173 shares of the biopharmaceutical company’s stock valued at $683,000 after purchasing an additional 46 shares in the last quarter. Institutional investors and hedge funds own 98.50% of the company’s stock.

Insider Activity at Madrigal Pharmaceuticals

In other news, insider David Soergel sold 1,042 shares of Madrigal Pharmaceuticals stock in a transaction on Monday, June 1st. The shares were sold at an average price of $495.74, for a total value of $516,561.08. Following the transaction, the insider directly owned 10,033 shares of the company’s stock, valued at $4,973,759.42. The trade was a 9.41% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard S. Levy sold 5,682 shares of the company’s stock in a transaction on Friday, May 22nd. The shares were sold at an average price of $515.44, for a total transaction of $2,928,730.08. Following the completion of the sale, the director owned 22,015 shares of the company’s stock, valued at approximately $11,347,411.60. This trade represents a 20.51% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 7,568 shares of company stock worth $3,880,711. 17.60% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on MDGL shares. Barclays set a $962.00 price objective on Madrigal Pharmaceuticals in a research note on Friday. Truist Financial lifted their price target on shares of Madrigal Pharmaceuticals from $640.00 to $709.00 and gave the stock a “buy” rating in a research note on Wednesday, May 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Madrigal Pharmaceuticals in a report on Friday, July 17th. Bank of America reduced their price objective on shares of Madrigal Pharmaceuticals from $550.00 to $542.00 and set a “neutral” rating on the stock in a report on Thursday, June 11th. Finally, HC Wainwright reiterated a “buy” rating on shares of Madrigal Pharmaceuticals in a research note on Friday. Fourteen investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Madrigal Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $688.20.

Key Madrigal Pharmaceuticals News

Here are the key news stories impacting Madrigal Pharmaceuticals this week:

• Positive Sentiment: Rezdiffra continues to drive strong revenue growth. Second-quarter revenue reached $364.25 million, up 71.2% year over year and above the $352.13 million analyst consensus, reflecting continued demand for the company’s MASH drug. Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates
• Positive Sentiment: The quarterly loss was narrower than expected. Madrigal reported a loss of $1.99 per share, beating estimates ranging from $2.55 to $2.68 per share, although the loss was wider than the $1.90-per-share loss recorded a year earlier. Madrigal Reports Q2 Loss, Beats Revenue Estimates
• Positive Sentiment: Analyst support remains favorable. Wells Fargo assigned Madrigal an Overweight rating, providing a positive signal for the company’s outlook. Madrigal Earns Overweight Rating from Wells Fargo
• Neutral Sentiment: Madrigal’s earnings call and quarterly presentation highlighted Rezdiffra’s contribution to the business and the company’s ongoing development efforts, but investors are weighing the pace of the commercial launch against the stock’s elevated valuation. Madrigal Q2 2026 Earnings Call Transcript
• Negative Sentiment: Shares fell despite the earnings beat. Investors appear concerned that Rezdiffra’s commercial growth is moderating, making the strong year-over-year revenue increase less compelling and raising expectations for evidence of sustained prescribing and sales momentum. MDGL Stock Down Despite Q2 Beat

Madrigal Pharmaceuticals Stock Performance

NASDAQ MDGL opened at $467.32 on Friday. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.50 and a quick ratio of 3.16. Madrigal Pharmaceuticals, Inc. has a 1 year low of $290.00 and a 1 year high of $615.00. The company has a market capitalization of $10.78 billion, a PE ratio of -36.25 and a beta of -1.05. The company has a fifty day moving average of $516.48 and a two-hundred day moving average of $499.05.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last posted its earnings results on Thursday, July 30th. The biopharmaceutical company reported ($1.99) EPS for the quarter, topping analysts’ consensus estimates of ($2.68) by $0.69. Madrigal Pharmaceuticals had a negative return on equity of 55.04% and a negative net margin of 25.32%.The business had revenue of $364.25 million for the quarter, compared to analysts’ expectations of $352.13 million. During the same quarter in the previous year, the firm earned ($1.90) earnings per share. The business’s revenue was up 71.2% compared to the same quarter last year. As a group, analysts expect that Madrigal Pharmaceuticals, Inc. will post -7.47 earnings per share for the current year.

Madrigal Pharmaceuticals Profile

Madrigal Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cardiovascular, metabolic and liver diseases. The company’s pipeline centers on novel, liver-directed agents designed to address significant unmet medical needs, with an emphasis on nonalcoholic steatohepatitis (NASH) and related metabolic disorders.

The lead product candidate, resmetirom (MGL-3196), is an orally administered, selective thyroid hormone receptor-? agonist in Phase 3 development for the treatment of NASH.